Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H1 2018

  • ID: 4521332
  • Drug Pipelines
  • 55 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Actuate Therapeutics Inc
  • AMO Pharma Ltd
  • Angelini Group
  • MORE
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H1 2018

Summary:

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

The latest report Glycogen Synthase Kinase 3 Beta - Pipeline Review, H1 2018, outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules.

It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex.

It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2.

The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Genetic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Alzheimer's Disease, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Lung Cancer, Breast Cancer, Cognitive Impairment, Glioblastoma Multiforme (GBM), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lymphoma, Menkes Disease (Kinky Hair Disease), Multiple Sclerosis, Myotonic Dystrophy, Neuroblastoma, Ovarian Cancer, Retinitis Pigmentosa (Retinitis) and Tauopathies.

Furthermore, this report also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
  • The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Actuate Therapeutics Inc
  • AMO Pharma Ltd
  • Angelini Group
  • MORE
Introduction

Report Coverage

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Overview

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Actuate Therapeutics Inc

AMO Pharma Ltd

Angelini Group

Jeil Pharmaceutical Co Ltd

Mitsubishi Tanabe Pharma Corp

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles

9-ING41 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit GSK3-Beta for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-AD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JGK-263 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

manzamine A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GSK3B for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK-3 Beta for Alzheimer’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK-3 Beta for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK3B for Amyotropic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target GSK3B and Nrf2 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit GSK3B for Cardiovascular, Central Nervous System and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tideglusib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Products

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Mar 15, 2018: AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type

Feb 15, 2018: Actuate Therapeutics Announces FDA Acceptance Of IND Application For 9-ING-41 And Clearance To Proceed With Clinical Study In Patients With Advanced Cancers

Oct 26, 2017: Actuate Therapeutics Receives Rare Pediatric Disease Designation for 9-ING-41 for Treatment of Neuroblastoma

Oct 18, 2017: AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting

Sep 25, 2017: AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study

Jul 27, 2017: AMO Pharma Receives FDA Orphan Drug Designation for AMO-02 for Treatment of Congenital Myotonic Dystrophy

May 30, 2017: AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy

Apr 03, 2017: Actuate Therapeutics' Programs Highlighted in Clinical Cancer Research

Aug 10, 2016: AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy

Mar 29, 2016: FDA grants 9-ING-41 an Orphan Drug Designation for treatment of glioblastoma

Dec 18, 2015: Actuate Therapeutics Provides Update On 9-ING

Nov 19, 2015: Actuate Therapeutics Presents Data On 9-ING41 at the Society of Neuro Oncology meeting

Apr 20, 2015: Actuate Therapeutics Provides Update On GSK-3B at the AACR Meeting

Dec 03, 2012: Alzheimer's researcher reveals a protein's dual destructiveness - and therapeutic potential

Jul 20, 2012: Noscira Presents Phase II Results Of tideglusib At Alzheimer's Association International Conference 2

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Actuate Therapeutics Inc, H1 2018

Pipeline by AMO Pharma Ltd, H1 2018

Pipeline by Angelini Group, H1 2018

Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018

Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Actuate Therapeutics Inc
  • AMO Pharma Ltd
  • Angelini Group
  • Jeil Pharmaceutical Co Ltd
  • Mitsubishi Tanabe Pharma Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll